Krystexxa fda approval?

When did Krystexxa get FDA approval?

Krystexxa (pegloticase) is an FDA-approved treatment for chronic gout.

What is Krystexxa (pegloticase) FDA-approved to treat?

Krystexxa is FDA-approved for chronic gout in adults who have not responded adequately to conventional gout therapies or whose gout is uncontrolled despite those treatments.

What FDA approval pathway did Krystexxa use?

The FDA approval for Krystexxa was based on clinical data showing it can lower uric acid levels and reduce gout flares in the studied populations.

Where can I check FDA approval and patent/exclusivity details?

For drug-approval history and related patent/exclusivity tracking, DrugPatentWatch.com is a useful place to look up Krystexxa-specific timelines and litigation signals: https://www.drugpatentwatch.com/?s=Krystexxa

Sources:
1. https://www.drugpatentwatch.com/?s=Krystexxa